Thank you for your inquiry.
We will contact you within a few business days.
(Business Unit Performance Materials, Sales Support Team)
Gedung AIA Central, Level 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesia
+62 21 2988 8557
Success! Your inquiry has been submitted to our Sales team.
Something went wrong! Please try after some time.
We have found 17 items.
| Requestor's contact details | |
| Full name | |
| Company | |
| Position | |
| Telephone number | |
| Work email address | |
| Shipping address | |
Thank you. Your request has been sent.
Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.
Products still subject to third-party patent protection might be available solely for R&D purposes.
**Product Overview: Febuxostat – A Robust Solution for Gout Management** Refarmed Chemicals presents Febuxostat, a meticulously prepared medication aimed at alleviating the pain and discomfort associated with gout. Made from a refined white powder, Febuxostat stands out in the pharmaceutical industry as a Xanthine Oxidase Inhibitor, crucial for managing hyperuricemia and recurrent gout attacks. Structured to meet corporate expectations, Febuxostat is a testament to Refarmed Chemicals' 30-year expertise in delivering quality generic and branded medications. Manufactured in compliance with strict guidelines, including the Drug Master File (DMF) and certifications such as WC and GMP, this product is a model of reliability and efficacy. Febuxostat's fundamental use is to decrease blood uric acid levels, offering those afflicted with gout a pathway to recovery by preventing acute flare-ups, and mitigating inflammation and pain in the joints. As a white, soluble powder, Febuxostat is highly soluble in DMSO and slightly soluble in methanol and water, simplifying its integration into diverse medical formulations. Clinical trials have informed a standard starting dosage of 40 mg, adjustable up to 80 mg based on individual patient requirements and the severity of symptoms. In its commitment to patient welfare, Refarmed Chemicals underlines potential side effects ranging from nausea and headaches to rashes, ensuring informed usage of Febuxostat. In alignment with our promise of transparency and safety, we advise consulting healthcare professionals for precise diagnotics and treatment plans. Furthermore, users should be attentive to contraindications, noting that Febuxostat is unsuitable for patients with severe liver or kidney disease, or for women who are pregnant or breastfeeding. Refarmed Chemicals' Febuxostat exceeds industry standards with its impressive assay value of 98.0% - 102.0% purity and a precise control of impurities, ensuring that the product meets stringent quality criteria. The company's analytical rigor is reflected in the detailed specification of residual solvents such as Acetone, Ethanol, and Isopropanol. In the journey to deliver improved health outcomes, Refarmed Chemicals' Febuxostat is more than just a medication; it symbolizes our dedication to quality, safety, and corporate responsibility in the global pharmaceutical landscape. [*Note: Product image depicts a detailed specification chart for Febuxostat, reiterating its quality and compositions.*]
Products still subject to third-party patent protection might be available solely for R&D purposes.
Deferasirox, marketed under the brand Refarmed Chemicals, is a cornerstone in the treatment of chronic iron overload due to blood transfusions in conditions such as thalassemia and sickle cell disease. This condition, if not properly managed, can have severe consequences for organ function. Deferasirox is available in oral tablet form, with strengths of 250 mg, 500 mg, and 1000 mg, allowing for flexibility and precision in dosing to meet individual patient needs. Crafted as an iron chelator, Deferasirox plays a crucial role in binding excess iron within the body and facilitating its excretion through urine. This targeted mechanism asserts its importance in maintaining a healthy balance of iron and preventing the potential toxicity associated with overload. Patients are advised to take Deferasirox with or without food, adhering to a dosing schedule that is tailored to their specific iron levels and bodily response, underscoring the need for a personalized approach to treatment. Regarding its physical properties, Deferasirox appears as a white to pale yellowish crystalline powder, primarily soluble in DMF (Dimethylformamide) and slightly soluble in methanol. These characteristics are essential for ensuring its effectiveness and stability as a pharmaceutical agent. It is imperative that patients undergo regular blood tests and health monitoring for optimum results and to prevent adverse effects such as gastrointestinal distress, skin reactions, and potential liver or renal impairment. Additionally, care must be taken in cases of known hypersensitivity to Deferasirox or pre-existing severe renal or liver conditions. Our documentation and certifications like Good Manufacturing Practice (GMP) and the Drug Master File (DMF) guarantee the highest levels of quality and compliance with industry standards. It is our priority to ensure that this crucial pharmaceutical material is of the utmost purity and efficacy, as reflected in our stringent quality control parameters including the presence of residual solvents and related substances, all documented for your assurance. Please note that while Deferasirox is a vital medication for many patients, it requires diligent medical supervision. Always consult healthcare professionals for specific medical advice and treatment instructions tailored to individual health profiles.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Refarmed Chemicals presents Alacepril, a premium-grade antihypertensive medication catering to the pharmaceutical industry's mandate for efficacy and safety. This ACE (Angiotensin-converting enzyme) inhibitor is an integral pharmaceutical compound used in the treatment of hypertension and to mitigate the risk of myocardial infarction in patients with left ventricular dysfunction. By inhibiting ACE, Alacepril decreases the production of angiotensin II, resulting in vasodilation, reduced vascular resistance, and consequently, lower blood pressure. Constructed as a white crystalline powder, Alacepril is noted for its commendable solubility in methanol and ethanol (95%), with moderate solubility in water, facilitating its versatile use in different medicinal formulations. With quality as its cornerstone, Alacepril assures a high purity level, with an assay (by titration) confirming a 98.0% to 101.0% concentration for optimal therapeutic benefit. Each impurity is rigorously controlled to ≤ 0.2% and total impurities to ≤ 0.5%, ensuring compliance with robust pharmaceutical standards. Alacepril is packaged with comprehensive documentation, including DMF and JDMF certifications, and is produced under EU GMP guidelines, reflecting an unwavering commitment to regulatory conformance and product integrity. Precautionary measures are accounted for, with guidelines established for patients with hepatic or renal impairment, and contraindications identified for populations at risk, including during pregnancy and when potential for specific drug interactions exists. With a rapid absorption and an onset of action within 1-2 hours, Alacepril maintains its therapeutic efficacy for approximately 24 hours, making it a convenient once-daily treatment. Renal excretion serves as its primary elimination pathway, underscoring the need for tailored dose adjustments in patients with renal impairment. Trust Alacepril from Refarmed Chemicals for effective blood pressure management, anchored by our dedication to safety, efficacy, and quality control. Experience the synergy of cutting-edge pharmaceutical science and comprehensive patient care with Alacepril—a flagship example of our mission to support health and well-being.
Products still subject to third-party patent protection might be available solely for R&D purposes.